WeTrials
Recruiting

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

What is this study?

This study is testing two different medication combinations to see which works better for advanced breast cancer that has specific genetic changes. Researchers want to find a more effective way to treat patients whose cancer has stopped responding to standard hormone therapies.

Who can participate?

Adult men and women of any menopausal stage with advanced ER+/HER2- breast cancer and an ESR1 gene mutation can join. Participants must have previously tried certain hormone treatments without their cancer progressing for at least six months.

What will happen?

Participants are randomly assigned to receive one of two treatment combinations: either the drug lasofoxifene combined with abemaciclib, or fulvestrant combined with abemaciclib. Both options involve taking daily pills, and one option also includes monthly injections.

Where and when?

The study is currently open and actively recruiting patients at multiple medical centers, including locations in Arizona and California. Your study doctor can provide the exact clinic details closest to you.

Key Points
  • 1Comparing two different hormone-blocking drug combinations with a targeted cancer therapy
  • 2Open to men and women with advanced ER+/HER2- breast cancer and a specific gene mutation
  • 3Currently recruiting participants at select locations in the United States

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Breast Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.